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ABSTRACT 
Rigorous glycaemic control – reflected by low HbA1c goals – is of utmost importance in the prevention and 
management of complications in patients with type 1 diabetes mellitus (T1DM). However, previous studies 
suggested that short-term glycaemic variability (GV) is important to consider as well, as excessive glucose 
fluctuations may have an additional impact on the development of diabetic complications. The potential 
relationship between GV and the risk for cardiovascular autonomic neuropathy (CAN), a clinical expression of 
cardiovascular autonomic dysfunction, is of increasing interest. This systematic review aimed to summarize 
existing evidence concerning the relationship between GV and cardiovascular autonomic dysfunction in T1DM. 
Electronic database search of Medline (Pubmed), Web of Science and Embase was performed, up to October 
2019. There were no limits concerning year of publication. Methodological quality was evaluated with the 
Newcastle Ottawa Scale for observational studies. Six studies (four cross-sectional and two prospective cohorts) 
were included. Methodological quality of the studies varied from level C to A2. Two studies examined the 
association between GV and heart rate variability (HRV) and both found significant negative correlations. 
Regarding cardiovascular autonomic reflex tests (CARTs), two studies did not while two other studies did find 
significant associations between GV parameters and CART-scores. However, associations were attenuated after 
adjusting for covariates such as HbA1c, age and disease duration. In conclusion, this systematic review found  
some preliminary evidence supporting an association between GV and cardiovascular autonomic dysfunction in 
T1DM. Hence, uncertainty remains whether high GV can independently contribute to the onset or progression of 
CAN. The heterogeneity in methodological approach made it difficult to compare different studies. Future studies 
should therefore use uniformly evaluated CGM-derived parameters of GV, while standardised assessment of HRV, 
CARTs and other potential cardiac autonomic function parameters is needed for an unambiguous definition of 
CAN. 
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Cardiovascular autonomic neuropathy ∙  Cardiovascular reflex tests ∙ Heart rate variability  
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BRS    Baroreflex sensitivity 
CAN    Cardiovascular autonomic neuropathy 
CART    Cardiovascular autonomic reflex test 
CGM    Continuous glucose monitoring 
CONGA    Continuous overlap net glycaemic action 
COV    Coefficient of variation 
DAN    Diabetic autonomic neuropathy 
DCCT    Diabetes Control and Complications Trial 
GV    Glycaemic variability 
HBGI    High blood glucose index 
HRV    Heart rate variability 
LBGI    Low blood glucose index 
MBG    Mean blood glucose 
MAG    Mean absolute glucose difference 
MAGE    Mean amplitude of glycaemic excursions 
MODD    Mean of daily differences 
SDT     Total standard deviation of glucose values 
T1DM    Type 1 diabetes mellitus 
 
RESEARCH IN CONTEXT BOX 
What is already known? 
• Short-term glycaemic variability (GV) is an integral component of glucose homeostasis in patients with 
type 1 diabetes (T1DM), next to HbA1c as a long-term measure of glycaemic control. 
• In-depth assessment of these blood glucose fluctuations is of increasing interest in latest years since 
previous research suggested a role in the development of diabetic complications.  
• Cardiac autonomic neuropathy is associated with higher morbidity and increased CVD mortality in type 1 
diabetes and assessment of heart rate variability and cardiovascular autonomic reflex function can be 
used as early screening strategies. 
What is the key question? 
• Does higher glycaemic variability independently contribute to the development of cardiovascular 
autonomic dysfunction in type 1 diabetes? 
What are the new findings? 
• High short-term GV might negatively affect heart rate variability (HRV). 
• The impact of GV on cardiovascular autonomic reflex function is less certain.  
Possible impact on clinical practice in the future? 
• Increasing attention should be pointed towards a glycaemic management that goes beyond HbA1c, aiming 
at a stable glucose homeostasis with less glycaemic fluctuations as it could be crucial in avoiding the 
vicious circle of deteriorating autonomic function, recurrent hypoglycaemia and its consequences. 
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However, there is an urgent need of more research concerning this matter, preferably long-term 
prospective studies. 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Strict glycaemic follow-up is of utmost importance in type 1 diabetes (T1DM) management to prevent or 
delay the onset of diabetic complications. Since chronic hyperglycaemia remains the main determinant of these 
complications, as proven by the Diabetes Control and Complications Trial (DCCT)1, HbA1c is still considered as the 
gold-standard measure of glycaemic control with a primary target to lower HbA1c as much as safely possible2. 
However, even if patients display similar HbA1c values and mean blood glucose, their glucose profiles may greatly 
differ3. The importance of these short-term fluctuations is of increasing interest in the past decade, which has led 
to a new concept: glycaemic variability (GV), a term referring to intra- and inter-day glycaemic fluctuations3-6. 
Concerning the methods to assess GV, older studies used 7-point capillary blood glucose profiles. 
Nowadays, continuous glucose monitoring (CGM) is considered as the number one method for the determination 
of short-term GV, with numerous metrics that have been established yet3,7. GV is generally subdivided in within-
day and inter-day variability3,7,8. To reflect within-day GV, total standard deviation (SDT), coefficient of variation 
(COV%) and mean amplitude of glucose excursions (MAGE) are recommended and most widely used, while the 
mean of daily differences (MODD) has been suggested to reflect between-day variability7,8. Besides, these 
measures can be complemented with the high and low blood glucose index (HBGI, LBGI), taking separately into 
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account the risk for hypo- and hyperglycaemic events9. Other metrics have also been proposed but are rarely 
used7,10-14.  
The role of GV in the development of diabetic complications is of increasing interest and should not be 
underestimated15-18, as some studies indicated that GV could independently contribute to microvascular 
complications19-21. A well-known complication is diabetic autonomic neuropathy (DAN), which affects the 
autonomic nervous system. Regarding the latter, damage to autonomic nerve fibres innervating heart and blood 
vessels can result in cardiovascular autonomic neuropathy (CAN), an important yet still underestimated 
problem22,23. Pathogenesis of CAN is complex, multifactorial and still under debate. Prevalence was reported to be 
between 15-35%23,24 and the most important risk factors include diabetes duration, high HbA1c and the 
conventional CV risk factors (hypertension, hyperlipidaemia and smoking)23-25. Clinical manifestations of CAN may 
range from latent signs such as nocturnal hypertension with non-dipping 26 to signs of resting tachycardia, 
exercise intolerance and more severe signs such as orthostatic hypotension, ECG abnormalities or even silent 
myocardial infarction 22,24,27. Detection of CAN is crucial as it is associated with high morbidity and mortality27-29, 
and can be evaluated by simple non-invasive methods: analysis of heart rate variability (HRV), cardiovascular 
reflex tests (CARTs) or baroreflex sensitivity (BRS)22,23,27,30. 
Some researchers suggested that GV may independently contribute to neuronal damage leading to the 
development of CAN. While studies in T2DM have already indicated that GV might influence cardiovascular 
autonomic function31-34, the evidence in T1DM is scarce. Given the previous research and gaps in existing 
literature, the purpose of this systematic review was to review the current evidence on the relationship between 
existing parameters of GV and cardiovascular autonomic dysfunction in patients with T1DM. 
 
 
METHODS 
This review was written according to the international PRISMA guidelines for reporting systematic reviews35. 
Eligibility criteria  
All studies that examined the association between parameters of GV and cardiovascular autonomic function in 
patients with T1DM were included (PICOS format). No restrictions were applied for age or disease duration of the 
patient population. All parameters used in current literature to express a degree of GV were accepted3,6. 
Considering cardiovascular autonomic function, several outcomes could be reported (HRV, CARTs,…). Articles 
could be written in English, French or Dutch and no limits were used concerning publication year of eligible 
studies. 
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Information sources and search strategy  
Studies were identified by electronic database search of Medline (PubMed), Web of Science and Embase. No 
filters were applied to these initial search strategies. Final searches on these databases were carried out on 
November 6th, 2018. The three searches were combined and duplicates removed. Additionally, a hand-searching 
was performed by checking the reference lists of obtained articles and an automatic search alert feed on PubMed 
and WoS notified whether new articles were published based on our search strategy, up to October 21, 2019. An 
overview of MeSH terms, keywords and final search strategies can be found in Appendix 1 (Table S1.) 
Study selection 
The screening team consisted out of four researchers and was divided into two groups of two people, with two 
researchers that screened first half of the articles and the second group evaluating the other part. A first 
screening was executed on title and abstract and a second screening on full-text. When screening was finished, a 
meeting was organized to discuss the results whereat any disagreements were resolved by oral discussion and 
consensus.  
Methodological quality assessment of individual studies 
To evaluate the risk of bias in selected studies, the Newcastle-Ottawa Scale for observational studies was used 
(Table 1) 36. All articles – both cohort and cross-sectional studies – were scored with the subscale for cohorts. This 
8-item checklist is subdivided into three domains: selection, comparability and outcome. Two researchers (S.H., 
K.V.W.) independently completed the checklist and subsequently discussed their results. Next, a level of evidence 
was assigned to each study following the EBRO (Evidence-Based Guideline Development) method 37. Each study 
was graded a level of evidence ranging from D up to A1, depending on EBM domain, study design and individual 
methodological quality. Consequently, the strength of conclusion (level 1-4) was assigned to the different 
outcome levels, taking into account the composition of the respective levels of evidence and consistency of their 
results 37. 
Data items and extraction 
Two researchers (S.H., K.V.W.) individually read the included articles and extracted data using a pre-determined 
data extraction form. Differences in data forms were resolved by consensus and all relevant information from the 
included studies was gathered and consistently summarized in the evidence table. The following data were 
extracted: (1) year of publication, (2) study design and - if present - follow-up period, (3) population 
characteristics, (4) parameters of GV, (5) outcome measures of cardiovascular autonomic function and (6) results 
for each outcome. 
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RESULTS 
Study selection 
The overview with the number of hits for each database search is shown in Supplementary Table S2. The 
combination of the three search strategies yielded 2574 hits and the hand-searching resulted in 2 additional 
studies. This was reduced to 2054 articles after removing duplicates. After the first screening, only 27 articles 
remained. The second screening resulted in a final number of 6 articles to be included. (Figure 1. Flowchart study 
selection) 
Study characteristics 
This review contains six eligible studies, of which four cross-sectional38-41 and two prospective cohort studies with 
a follow-up of 3 and 10 years42,43. The sample size of the cross-sectional studies varied between 20-80 patients 
and the cohort studies included respectively 41 and 1375 patients 42,43. All six studies included adults, with a mean 
age range between 27-47 years. Mean HbA1c values were similar between different study populations, within a 
range of 64-75 mmol/mol (8-9%) and mean time since diagnosis varied from 2.6 to 17.5 years. Considering the 
methods for determination of GV, five studies used CGM 38-42 for a duration between 1-6 days, while one study 
used 7-point capillary blood glucose profiles at 3 months intervals 43. SD and MAGE of glucose values were the 
most studied parameters of GV, determined in five studies 38,40-43. Hypoglycaemic indices (LBGI, AUC hypo and %-
time in hypo) were reported in three studies 39,40,42. COV glucose and M-value (two studies); CONGA, MODD and 
MAG (one study) were used less frequently. All studies used CARTS or HRV to assess cardiac autonomic function, 
except one that examined blood pressure dipping 42. Three studies also determined whether or not CAN was 
present, all of them basing CAN diagnosis on the results of CARTs 40,41,43. 
Risk of bias within studies 
Since it is impossible for T1DM patients not to demonstrate GV as it is omnipresent in this population, the ‘non-
exposed cohort’-criteria were not assessed, i.e. it was not applicable to score questions 2 and 5 of the NOS scale 
(‘Selection of non-exposed cohort’ and ‘Comparability of cohorts’, respectively). Question 3 (Ascertainment of 
exposure) was scored positive for all studies that used CGM since a complete glucose data profile is obtained 
which objectively reflects GV. The most common positive scored question was ‘Ascertainment of exposure’ (five 
studies) and ‘Assessment of outcome’ (all studies). One included publication obtained level of evidence A2 43, one 
study level B 42 because of lacking the required A2 criteria 37 and a level C was granted to all four cross-sectional 
studies since these were non-comparative 38-41. Results of risk of bias assessment are shown in Table 1. 
Consequently, a level of conclusion 3 was assigned to the two outcomes, HRV and CARTs (Synthesis of results). 
Summary of individual study results 
An overview of all individual studies is shown in Table 2 and their key findings are presented in Table 3. 
Synthesis of results: Relationship between GV and cardiovascular autonomic function in T1DM 
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          Association between GV and HRV parameters.   Two studies examined the relationship between short-term 
GV (both based on CGM) and HRV and both found significant negative associations38,39. Significant negative 
associations between higher hypoglycaemic indices and LF power as a frequency-domain measure of HRV (LBGI-
LF power: R2= 0.351; AUC hypo-LF power: R2= 0.316), were reported in a population without evidence of diabetic 
complications39. Other research found significant negative correlations between COV-RR (time-domain HRV) and 
intraday GV parameters (r= from -0.38 to -0.65), which was especially pronounced during night-time 38. Thus, high 
short-term GV might negatively affect HRV (level of conclusion 3).  
          Association between GV and CART parameters.   Four studies evaluated CART parameters, as determinants 
of cardiovascular autonomic function or to assess whether or not CAN was present39-41,43, but showed ambiguous 
results (level of conclusion 3). One study did not find significant associations between hypoglycaemic indices and 
CART-ratios39, and the prospective cohort study based on data from the DCCT found no significant association 
between within-day GV (from 7-point capillary blood glucose) and the risk for CAN after adjusting for MBG43. Two 
more recently published studies (2018) both reported significant associations between GV and CAN, however, 
they did not completely confirm each other as they used different covariates in statistical analysis. The study of 
Njiraty et al. found a tendency of higher GV in the CAN group (n=10/20), as well as significant positive correlations 
between two GV parameters (SD, MAG) and CAN-scores (based on CARTs; r= from 0.47 to 0.62), but only one 
remained significant (SD glucose – SBP fall; r= 0.49) after adjusting for HbA1c, age and disease duration41. On the 
other hand, the study of Jun et al. in 80 patients found that several parameters of GV (SD, COV, MAGE, LBGI, 
HBGI, %-time in hypoglycaemia and AUC hypo) were independently associated with CAN, all of this after adjusting 
for MBG and clinical risk factors. Level 2 hypoglycaemia (<54 mg/dl) showed the highest relative contribution to 
this association in this study (standardized weight= 0.4135; p= 0.001)40. 
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DISCUSSION 
Statement of principal findings: summary of evidence 
This systematic review examined the association between GV – a concept increasingly gaining attention – and 
CAN, a clinical expression of cardiovascular autonomic dysfunction and an underestimated problem in T1DM. The 
scarcity of data (only 6 studies), together with the null finding from prospective studies, makes it hard to draw 
solid conclusions and points to an urgent need for more research into this relationship. Concerning the impact of 
GV on HRV, as a measure of CAN, high short-term GV might negatively affect parameters of HRV as shown by two 
cross-sectional studies (level of conclusion 3)38,39. Regarding the association between GV and the results of CARTs 
as determinants of cardiovascular autonomic function, ambiguous results were reported by included studies40-43. 
While two studies did not find significant associations between GV indices and CART-parameters after adjusting 
for mean blood glucose (MBG)39,43, two more recent studies however, did found significance40,41. Hence, 
uncertainty remains about the impact of GV on cardiovascular autonomic reflex function (level of conclusion 3). 
Methodological considerations of GV and CAN assessment – Strengths and weaknesses of included studies 
Heterogeneity in methodological approach – both for GV and CAN assessment – makes it difficult to fully compare 
the different study results and therefore hard to draw solid conclusions about their relationship.   
          Cardiovascular autonomic function. Regarding HRV, assessment should take place under well-standardised 
conditions as recommended by the Task Force on HRV44. Spectral analysis of RR-intervals (for determination of 
frequency-domain HRV) is most valid and reliable if monitored under resting conditions (concept of stationarity), 
preferably after ten minutes of supine rest in a darkened room and abstained from nicotine, caffeine or 
pharmacologic agents that interfere with HR or blood pressure44. Once again, this is often not reported in studies. 
HRV assessment should comprise both time- and frequency-domain measures. This was not the case in two 
studies, with the evaluation of only time- or frequency-domain HRV, respectively38,39. From the existing 
multiplicity of time-domain measures, the Task Force recommends four of them (SDNN, SDANN, HRV triangular 
index and RMSSD) 44. Furthermore, it is not useful to compare time-domain measures obtained from recordings of 
different durations. Duration should be standardized and a short-term five-minute resting evaluation or an entire 
24h-recording are both useful44,45. Also for CARTs, studies should strictly follow recommendations on how to 
perform and interpret these tests since several confounding factors have been identified46,47.  
          CAN diagnosis: clear cut case or tricky business? Next to the heterogeneity in HRV analysis and CART 
evaluation, the diagnosis of CAN is not unambiguous as well47. Moreover, this differed between included studies 
as other criteria were used for CAN diagnosis. All studies based CAN diagnosis on the results of CARTs, however 
with different interpretations of these tests40,41,43. Although different criteria for CAN are found in literature, 
studies should adhere to one clear algorithm47. CARTs, if executed correctly, are considered the gold-standard in 
CAN diagnosis since they are safe, non-invasive and can be well-standardized23,24. The traditional classification in 
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early, confirmed and severe CAN remains useful 47-49 but an ‘autonomic neuropathy score’ – obtained by scoring 
the results of CARTs – is advised because of its dual advantage of evaluating the progression of CAN and providing 
an overall quantitative result46. Secondly, HRV monitoring is a valuable tool for assessing cardiovascular 
autonomic function, with some researchers even claiming that it is the most sensitive and specific method50,51. 
HRV could detect early changes in myocardial autonomic innervation and thus CAN in sub-clinical stages23,52,53, 
even in young patients54. In our opinion, both HRV analysis and CARTs should be performed in order to have 
extensive insight into patients’ cardiovascular autonomic function and potential CAN diagnosis23,24,47. Moreover, 
by evaluating both HRV and CARTs, the cardiovascular branches of the ANS are examined at rest as well as under 
stress conditions, as resting HRV reflects the sympathetic and parasympathetic HR modulation while the CARTs 
mainly evaluate the capacity of the cardiovascular reflexes to react on stimuli. Moreover, assessment of 
cardiovascular autonomic function can also comprise other aspects, such as evaluation of baroreflex function 
measured by baroreflex sensitivity (BRS). As BRS was found to be reduced in T1DM55-57 and able to differentiate 
patients with CAN from those without58, it could be a valuable adjunct in reflecting cardiovascular autonomic 
function58,59. BRS can be estimated non-invasively through analysis of spontaneous beat-to-beat fluctuations of BP 
and R-R interval lengths on ECG59.  
          Non-dipping blood pressure: phenomenon needing attention. The clinical importance of this aberrant BP 
pattern is well-known since non-dippers showed a higher incidence of cardiovascular events and target organ 
damage60,61. There is still uncertainty about the exact pathogenesis of this loss of normal nocturnal BP decrease. 
Hypertension, renal function impairment and altered nocturnal sympathovagal balance are often linked to the 
aetiology of non-dipping61,62 and non-dipping is sometimes considered as a surrogate measure of CAN63-66. 
Concerning the role of GV, higher postprandial BG excursions were found to be related to non-dipping in T2DM, 
with both endothelial and autonomic nervous dysfunction (sympathetic overdrive) proposed as potential 
mechanistic linkages64. In this review, only one study examined the association between non-dipping and GV but 
did not found significance, not at baseline nor after follow-up42. However, this was only for three years, which 
might have been too short to detect any significant association. Still, the authors stated that GV can act as a 
potential risk factor driving non-dipping, which may lead to silent CVD42. In the future, mechanisms of non-
dipping, as well as the associations between abnormal diurnal variation in BP and blood glucose, need further 
research. 
          Assessment of glycaemic variability. Only CGM provides a full picture of short-term glucose fluctuations and 
consequently captures the full degree of GV, as CGM-outputs comprise 5-min interval glucose values from which 
all existing parameters can be calculated67,68. The 7-point capillary BG profile on the other hand, used in the study 
of Lachin et al. with data from the DCCT43, is insufficient to characterize GV correctly, as the validity of this 
method is strongly dependent on the timing and number of finger prick measurements throughout the day and 
often many data points are missing69-71. However, multiple imputation methods were used in the study of Lachin 
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et al., making their results somewhat more reliable43. Regarding the use of CGM in research, the system should be 
used for at least seven days68, which conflicts with two studies that only implemented CGM for two and three 
days, respectively38,40. Besides this, to get a reliable picture of the everyday GV of a patient, standardised 
instructions are needed. Patients should retain their normal activities of daily living including usual eating habits 
and physical activity level, which is often not specified in the methodology section of included studies. 
           The plethora of existing GV parameters: bless or burden? Many different parameters were used in the 
included studies to reflect GV, but one should be cautious when interpreting or comparing results of studies since 
not all indices are equivalent as they can represent different concepts72. Some of these parameters are highly 
correlated and actually comprise the same information, while others do not73. A combination of the most relevant 
indices is necessary to effectively describe GV. For example, COV is more valid than SD in reflecting overall GV74 
and more sensitive in predicting hypoglycaemia9,74, while the MAGE index mainly reflects mealtime-related GV7. 
The importance of avoiding excessive post-meal glucose excursions is evidently acknowledged since this 
substantially contributes to hyperglycaemic exposure and thus MBG75. Therefore, the advantage of MAGE is that 
it only assesses major glucose swings and excludes minor ones, being considered as a measure of unstable 
diabetes76. Also between-day GV – assessed by the MODD – needs further investigation. In this review, however, 
only one study reported this parameter38. In conclusion, future studies should focus on standardizing the methods 
for GV assessment and its two most important components: amplitude and timing68,77. A uniform set of GV 
parameters is needed and studies should separately report the results per parameter. Fabris et al. showed that 
more than 25 parameters could be reduced to a set of 10, comprising all necessary information on GV78. More 
studies are needed to examine which of these GV parameters offer advantage in predicting diabetic 
complications72. Importantly however, most of aforementioned parameters (SD, MAGE, MODD) are still 
dependent on mean glycaemia. Simply adjusting for MBG might not be enough to exclude the possibility that the 
observed association actually comes from the difference in MBG. COV and MAG at the contrary are not 
dependent on MBG and have been recommended by DeVries et al. to reflect true glucose variability79. Taking this 
into consideration and looking closer at included studies, we evaluated the impact of excluding the mean-
dependent CGM-parameters. Iwasaki et al.38 assessed only mean-dependent parameters (SD, MAGE, M-value, 
MODD), which makes this small cross-sectional study somewhat less robust. Also for the study of Njiraty et al.41, 
uncertainty increased if we exclude SD glucose as parameter for GV, as this was the only remaining significant 
correlation in the multiple regression model. On the other hand, interpretation of the study results of Jun et al.40 
(assessing SD, MAGE and COV) did not change, as COV was significantly associated with CAN risk in all regression 
models. 
          Hypoglycaemia as underlying disturbing factor. Lowering patient’s MBG is only possible if GV is constrained, 
otherwise BG fluctuations would inevitably enter the range of hypoglycaemia80. Increased hypoglycaemia due to 
excess GV has been demonstrated in several studies, showing GV to be a predictor of hypoglycaemic events78,81,82. 
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Therefore, it is interesting to explore whether the increased hypoglycaemia is more important than GV itself and 
whether it is independently associated with the outcomes of interest. Hypoglycaemia was found to be associated 
with lengthening of the QTc interval on ECG83,84 and reduction of cardiac vagal outflow with diminished HRV85-87. 
Hence, the impact of hypoglycaemia on cardiac autonomic regulation should not be neglected88. In this review, 
two studies evaluated parameters describing hypoglycaemia and both found significant results39,40. However, 
several parameters can characterise hypoglycaemia: area under the curve (AUC hypo), %-time spent in 
hypoglycaemia, number of hypoglycaemic events or the LBGI (risk index). The study of Jun et al. found significant 
results for all of these hypoglycaemic parameters40. Once again, these indices are not equivalent as they reflect 
different aspects. The AUC hypo gives complete insight into the severity of hypoglycaemia since there is a 
contribution from both time of exposure and level of hypoglycaemia; while time spent in hypoglycaemia (%) only 
reflects total duration but not severity. Separate monitoring of time in level 2 hypoglycaemia (<54 mg/dl)  showed 
the highest contribution to the reported associations and can provide a solution for this issue40. Hence, future 
studies should further elucidate the importance of (level 2) hypoglycaemia, next to parameters of GV. 
Covariates in the relationship between GV and CAN . Lastly, as with many studies, study populations were 
rather heterogeneous: from adolescents89 to complication-free patients39,40,42 and patients with established 
complication status38,41. The question remains if results can be generalised for the entire patient spectrum since 
the effects of GV could vary throughout the broad range of disease duration and complication status. These 
aspects should be as much as possibly adjusted for in statistical analysis but varied widely between included 
studies. While Jun et al. used age, HbA1c and disease duration as covariates40, the study of Njiraty et al. adjusted 
for smoking, BMI and SBP41 and Virk et al. also adjusted for body height and socio-economic status89. Future 
studies should uniformly adjust only for the known risk factors of CAN (as pointed out previously in the 
introduction of this review) as covariates in their analyses and thereby decrease the risk for overfitting. 
Role of GV in diabetic complications: time to shed clarity on this unanswered question? 
          Regarding the underlying pathophysiology, the frequent occurrence of both excessive glucose decrements 
and increments increases the amount of oxidative stress and inflammatory markers, which was reported to be the 
key mediator in the detrimental effect on vascular and nerve function8,18,90-94. While some in vitro studies found 
that acute glycaemic swings can induce endothelial cell damage via excessive formation of free oxygen radicals95, 
in vivo research did not confirm this association between high GV and increased oxidative stress (by urinary 
excretion rates of 8-iso-PGF2α) in T1DM patients96. The term Pyramid of the Risk was introduced after the finding 
that GV – next to the classic glucose triad of mean, fasting and postprandial BG – may also have deleterious 
effects on the development of diabetic complications97. Previous reviews concluded that GV has if any, only 
minimal impact on the development of diabetic complications, however, most of the studies in these reviews re-
analysed data from the DCCT in which GV was determined using 7-point capillary BG profiles and not CGM15,16. A 
recent review from The Lancet concluded that it has not yet been definitively confirmed whether GV is an 
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independent risk factor for diabetes complications6. Concerning the relationship of GV with CAN in T1DM in 
particular, only a few studies focused on this association, all of them included in this review. 
          Causality and importance of the relationship between GV and cardiovascular autonomic dysfunction. The 
cross-sectional nature of many studies prevents inferring a causal relationship. Furthermore, one can also 
question the direction of this possible association, i.e. ‘what is cause and consequence and vice versa?’. While GV 
may negatively impact sympathovagal balance by increasing oxidative stress as mentioned before22,98, autonomic 
dysfunction on the other hand may reciprocally affect GV due to disturbed glucose counter-regulation and 
decreased hypoglycaemic awareness88,99. These latter two are often present in long-standing T1DM and may 
result in even more pronounced fluctuations and hypoglycaemic events100,101. In summary, the direction of the 
association remains to be elucidated, but is perhaps bidirectional as it is not clear whether autonomic dysfunction 
drives GV or the other way around.  
Strengths and limitations of this review 
This systematic review comprises a comprehensive literature search up to 2019 with extensive search strategies 
on three major databases. The methodological quality of included studies was carefully and critically assessed 
with levels of evidence based on the risk of bias. Finally, we present a thorough discussion of important 
methodological considerations as well as implications for further research. Potential limitations of this review 
could include the limited amount of studies – with four cross-sectional and two prospective studies – and 
inclusion of only articles written in English, French or Dutch. 
 
CONCLUSION 
This systematic review found some preliminary evidence supporting the hypothesis of an association between GV 
and cardiovascular autonomic dysfunction in T1DM. The scarcity of data (only 6 studies), together with the null 
finding from prospective studies, makes it hard to draw solid conclusions and points to an urgent need for more 
research into this relationship. At this moment, uncertainty remains whether high GV can independently 
contribute to the onset or progression of CAN. The heterogeneity in methodological approach makes it difficult to 
compare different studies. Future studies should therefore use uniformly evaluated CGM-derived parameters of 
GV, while standardised assessment of HRV, CARTs and other potential cardiac autonomic function parameters is 
needed for an unambiguous definition of CAN. 
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STUDY (DESIGN) 
CRITERIA 
 
INDIVIDUAL 
STUDY 
QUALITY: LEVEL 
OF EVIDENCE 
1 3 4 6 7 8  
Jaiswal et al. (2014) 
(cross-sectional) 
- + / + / / C 
Iwasaki et al. (2015) 
(cross-sectional) 
+ + / + / / C 
Lachin et al. (2017) 
(prospective cohort) 
+ - + + + + A2 
Nyiraty et al. (2018) 
(cross-sectional) 
+ + / + / / C 
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Jaiswal et al. (2018) 
(prospective cohort) 
- + ? + ? + B 
Jun et al. (2018) 
(cross-sectional) 
+ + / + / / C 
Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies 
Selection of cohort(s):    1: Representativeness of the exposed cohort; 3: Ascertainment of exposure; 4: Demonstration 
that outcome was not present at start of the study;  
Outcome assessment:    6: Assessment of outcome; 7: Follow-up long enough for outcomes to occur; 8: Adequacy of 
follow-up of cohorts 
“+”: yes;         “-“: no;        “?”: unknown, not mentioned or uncertain;        “/”: not applicable to score      
NOTE: Since it is impossible not to demonstrate glycaemic variability, there was no ‘non-exposed cohort’ present in the 
included studies, making it not applicable to score questions 2 and 5 of the NOS scale (‘selection of the non-exposed cohort’ 
and ‘comparability of the cohorts’, respectively).   
TABLE 1.    Risk of bias assessment in individual studies.
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    First 
author 
(year of 
publication) 
Study design 
(Follow-up) 
Population characteristics 
Glycaemic variability: 
method of assessment 
& parameters 
Cardiovascular autonomic 
function: outcomes 
Results 
Jaiswal et al.39 
(2014) 
Cross-sectional 
analysis baseline  
(/) 
n= 44    (17 M, 27 F) 
Age: 34 ±13 yrs (range:18-65) 
DD: 13 ± 6 yrs (all >5 yrs) 
BMI: 26 ± 4  
HbA1c: 64 mmol/ mol (8.0 ± 
1.2%) 
TDI: 0.7 ± 0.2 U/kg/day 
 
CGM for 5 days 
 
Indices of hypoglycemic 
stress 
 LBGI 
 AUC for 
hypoglycaemia (<70 
mg/dl) 
HRV (rest and during CART) 
    LF power 
    HF power 
CARTs 
    Deep breathing: E:I-ratio 
    Valsalva ratio 
    Standing: 30:15 ratio 
 
Correlations between hypoglycaemic indices and HRV 
   → LBGI: Significant correlations with LF power (r=-0.47; p=0.002**)    
        and HF power (r=-0.37, p=0.018*) 
    → AUC: Significant correlations with LF power (r=-0.43; p=0.005**)  
       and HF power (r=-0.38; p=0.015*) 
Linear regression: 
    Unadjusted model: all associations significant 
    → LBGI – LF power: R2=0.220; LBGI – HF power: R2=0.135 
    → AUC hypo – LF power: R2=0.185; AUC hypo – HF power: R2=0.143 
    Adjusted models:  
    → All associations with LF power persisted after adjusting for HbA1,   
         age, DD, BMI (LBGI: R2=0.351; AUC hypo: R2=0.316) 
    → Associations with HF power remained significant in adjusting model  
         for HbA1c (LBGI: R2=0.199; AUC hypo: R2=0.207), but disappeared    
         after adjusting for other covariates (NS) 
    → No significant associations between LBGI/AUC and CART ratios 
Iwasaki et 
al.38 
(2015) 
 
 
Cross-sectional  
(/) 
n=  31    (13 M, 18 F) 
Hospitalized 
Age: 47.2 ± 16.4 yrs 
DD: 18.6 ± 12.8 yrs 
BMI: 22.4 ± 3.7 
HbA1c: 64 mmol/mol (8.0 ± 
1.5%) 
MDI: n=20, CSII: n=11 
 
CGM for >24 h (56.5 ± 
15.3h)  
 
Intraday GV 
 SD glucose 
 MAGE 
Hybrid: MBG & GV 
 M-value 
Inter-day GV (2days) 
 MODD 
HRV 
    COV of RR-interval 
Correlations between COV-RR and GV measures 
    → Significant correlations with whole day SD (r=-0.50; p=0.007**),  
         MAGE (r=-0.47; p=0.011*), M-value (r=-0.38; p=0.048*) and MODD  
         (r=-0.59; p=0.001***) 
    → Significant correlations with nighttime SD (r=-0.59, p=0.001***),  
         MAGE (r=-0.47; p=0.011*), M-value (r=-0.53; p=0.004**) and  
         MODD (r=-0.65; p=0.0003***) 
    → Significant correlations with daytime SD (r=-0.44; p=0.019*) and  
         MAGE (r=-0.50; p=0.006**); No significant correlation with daytime  
         M-value and MODD (NS) 
Lachin et al.43 
(2017) 
Prospective 
cohort 
n= 1375    (M/F: almost equal) 
Age: 27 ± 7 yrs 
7-point capillary blood 
glucose measurement, 
CAN - based on: CARTs 
    Deep breathing: ∆RR-int. 
Longitudinal logistic regression model for repeated measures, using 
Generalized Estimating Equations for CAN over 2, 4, 6 and 8 yrs follow-up 
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1983 - 1993 
(10 yrs) 
 
DD: 1-15 yrs (all) 
  Primary prevention   
  group: 2.6 ± 1.4 yrs 
  Secondary prevention   
  group: 8.7 ± 3.8 yrs 
HbA1c: 74 mmol/ mol (8.9%) 
TDI: 0.62-0.71 ± 0.23   
  U/kg/day respectively  
No CAN at baseline 
Every 3 months 
 
Within-day GV 
 SD glucose 
 MAGE 
 M-value 
 
    Valsalva ratio 
    Standing: DBP drop 
CAN if <predefined cut-offs 
on at least one CART 
CAN assessment: at baseline 
and after 2,4,6,8 years of 
follow-up 
 
   → Unadjusted model: CAN significantly associated with MAGE  
        (p=0.017*) and M-value (p=0.046*)  
   → After adjusting for MBG: None of the measures of      
        within-day GV (SD glucose, MAGE, M-value) remained significantly 
        associated with CAN (p=0.20; p=0.06; p=0.10) 
 
Nyiraty et 
al.41 
 (2018) 
 
 
 
 
 
 
 
Cross-sectional  
(/) 
n= 20    (6 M,  14 F) 
Age: 39.5 ± 3.4 yrs 
DD: 17.5 ± 2.5 yrs 
BMI: 22.3 ± 0.8 
HbA1c: 65 mmol/mol (8.1 ± 
0.7%) 
TDI: 42.8 ± 2.9 U 
All treated w/ MDI 
 
CGM for 6 days 
 
 SD glucose 
 MAGE 
 CONGA 
 MAG 
CAN & CAN-score (/10) - 
based on: CARTs 
CARTs 
     Deep breathing: ∆HR 
     Valsalva ratio 
     Standing: 30:15 ratio 
     Standing: SBP drop 
     Handgrip: DBP rise 
CAN if score ≥2/10 
Between-groups-analysis: CAN vs no CAN-group 
     → No significant difference in GV parameters between 2 groups;      
          although tendency of higher GV in CAN group (n=10) 
Correlations between GV measures and CARTs/CAN 
     → SD glucose: significant correlations with CAN-score (r=0.47; p<0.05*)  
          and SBP drop (r=0.51; p<0.05*) 
     → MAG: significant correlations with CAN-score (r=0.62; p<0.01**),         
          30:15 ratio (r=-0.50; p<0.05*) and SBP-drop (r=0.59; p<0.01**) 
     → MAGE & CONGA: no sign. correlations with CAN-score or CARTs 
Multivariate linear regression 
     → After adjusting for HbA1c, age and DD → one correlation remained  
          significant: SD glucose – SBP drop (r=0.49; p<0.05*) 
Jaiswal et al.42 
 (2018) 
 
 
 
Prospective 
cohort 
(3 yrs) 
 
n= 41    (16 M,  25 F) 
Age: 34 ±13 yrs (range:18-65) 
DD: 13 ± 6 (All DD >5 yrs) 
BMI: 26 ± 4  
HbA1c: 64 mmol/ml (8.0 ± 
1.2%) 
TDI: 0.7 ± 0.2 U/kg/day 
 
 
CGM for 5 days 
Every 3 months 
 
 COV glucose 
 MAGE 
 LBGI & HBGI 
 AUC for 
hypoglycaemia 
 AUC for 
hyperglycaemia 
Blood pressure dipping (%) 
ABPM assessment: every year 
Between-groups-analysis at baseline: Non-dipping group (n=4) vs Dipping 
group (n=37): 
     → No significant differences in GV measures  
Correlations at baseline 
     → No significant correlations at baseline between BP dipping-% and  
         GV measures 
Between-groups-analysis after 3 yrs: Progressors group (n=24) vs Non-
progressors group (n=17): 
     → No significant differences in GV measures 
Jun et al.40 
(2018) 
Cross-sectional  
(/) 
n= 80    (35 M, 45 F) 
Age: 39.9  ± 14 yrs 
CGM for 3 days, of which 
middle 48h used 
CAN - based on: CARTs 
     Deep breathing: EI-ratio 
Between-groups-analysis: CAN-group (n=36) vs No CAN-group (n=44): 
  → Higher SD (p<0.001***), COV (p=0.007**) and MAGE (p=0.003**) 
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DD: 10.1 ± 7.3 
BMI: 22.6 ± 3.2 
HbA1c: 66 mmol/mol (8.2 ± 
1.7%) 
TDI: not mentioned 
MDI: n=60; CSII: n=3;     
  only basal: n=17 
Smoking: n=5 
 
 
 
 
GV: 
 SD glucose 
 COV glucose 
 MAGE 
 LBGI & HBGI 
 
Hypoglycaemic stress: 
 AUC for 
hypoglycaemia 
 AUC for 
hyperglycaemia 
 %-time 
hypoglycaemia 
 %-time 
hypoglycaemia 
 %-time nocturnal 
hypoglycaemia 
 
     Valsalva ratio 
     30:15 ratio 
     Standing: SBP drop 
CAN if: 2/3 abnormal 
parasympathetic CARTs  or 
orthostatic hypotension 
  → More extreme peak and nadirs were observed in CAN group 
  → Higher %-time in level 2 hypo (p=0.001***), AUC for level 2 hypo  
  (p=0.001***), %-time in nocturnal level 2 hypo (p=0.001***), number of 
nocturnal level 2 hypo episodes (p=0.008**) and LBGI (p=0.004**)  
  → Higher AUC for level 2 hyper (p=0.008**) and HBGI (p=0.003**) 
Multivariate logistic regression: Associations CGM parameters and CAN risk 
   Model 1: adjusting for age, sex, BMI, SBP, HbA1c, LDL, current smoking  
                    status, DD and use of antihypertensive drugs 
   Model 2: further adjusting for MBG 
                                      ↓ 
GV/CGM parameters that increase risk for CAN: 
→ SD (OR=1.05; p=0.005**), COV (OR=1.11; p=0.001***) and MAGE (OR=1.02; 
p=0.019*)  
→ AUC for level 2 hypo (OR= 3.19, p=0.001***), %-time in level 1 and 2 hypo 
(OR= 7.55, p=0.020*; OR= 38.60, p=0.001***), %-time in nocturnal level 1 and 
2 hypo (OR=7.55, p=0.020*; OR= 113.24, p=0.001***) 
→ LBGI (OR= 1.29; p=0.001***) and HBGI (OR= 1.23; p=0.01**) 
Predictive value of CGM parameters for CAN after adjusting for MBG (model 2) 
    → %-time in level 2 hypo and nocturnal level 2 hypo highest predictive value  
         for CAN (p<0.001***); AUC for level 2 hypo & LBGI follow with also  
         strong predictive value (p<0.001***); SD, COV, MAGE and HBGI also  
         significant (p=0.003**; p=0.001***; p=0.017*; p=0.012*) 
Relative contribution of CGM parameters (dominance analysis) 
    → %-time in level 2 hypo (model 1) and %-time in nocturnal level 2 hypo  
         (model 2) highest ranked variables (standardized weight 0.4135 and  
          0.3636) 
Level of significance:   *: p<0.05;  **: p<0.01;  ***: p<0.001;  (NS): not significant 
Table legend: 
n: sample size; M/F: male/female; yrs: years; DD: diabetes duration (time since diagnosis, yrs); MBG: mean blood glucose; BMI: body mass index (kg.m-2); TDI: total daily insulin dose; MDI: multiple daily 
injections of insulin; CSII: continuous subcutaneous insulin infusion (insulin pump); CVD: cardiovascular disease; CKD: chronic kidney disease; CGM: continuous glucose monitoring; GV: glycaemic variability; 
SD: standard deviation; COV: coefficient of variation (SD/MBG); MAGE: mean amplitude of glycaemic excursions; MODD: mean of daily differences; LBGI/HBGI: low/high blood glucose index; AUC: area 
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under the curve; CAN: cardiac/cardiovascular autonomic neuropathy; HRV: heart rate variability; LF/HF: low/high frequency; CART: cardiovascular autonomic reflex test; E:I-ratio: expiration:inspiration-ratio; 
SBP/DBP: systolic/diastolic blood pressure; ABPM: ambulatory blood pressure monitoring; OR: odds ratio 
TABLE 2.  Evidence table: Results of included studies assessing the relationship between glycaemic variability and cardiovascular autonomic function in type 1 diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
First author 
(year of publication) 
Study design 
(Follow-up) Key findings & Main conclusions 
Jaiswal et al. (2014)39 
Cross-sectional 
analysis at baseline 
Increased GV promoting hypoglycemic stress is associated with reduced HRV, independent of glycemic control as assessed by HbA1c. 
Inverse associations persisted after adjusting for HbA1c but attenuated by age, DD and BMI. 
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TABLE 3.    Main conclusions of included studies. 
 
Iwasaki et al. (2015)38 Cross-sectional 
COV-RR, as a parameter of HRV, is closely associated with GV, showing negative correlations with whole-day, daytime and – especially – 
nighttime variables of GV. 
Lachin et al. (2017)43 
Prospective cohort 
1983 – 1993 (10 
yrs) 
Overall, within-day GV (determined from quarterly glucose profiles) does not play an apparent role in the development of CAN (based on 
three CARTs) beyond the influence of MBG. Adjusted for MBG, no measure of within-day variability was associated with any outcome. 
Nyiraty et al. (2018)41 Cross-sectional 
GV (on CGM) correlates with both parasympathetic and sympathetic dysfunctions (CAN score, orthostatic SBP fall, CARTs). Increasing 
values of SD and MAG are observed in the presence of more severe CAN. 
Jaiswal et al. (2018)42 
Prospective cohort 
2014-2017 (3 yrs) 
No significant correlations were found at baseline between non-dipping nocturnal blood pressure and measures of GV, and GV did not 
explain differences in the risk for progression to non-dipping over time. 
Jun et al. (2018)40 Cross-sectional 
CGM-defined GV is associated with CAN (CARTS, orthostatic hypotension) independent of MBG and other clinical risk factors for CAN. 
The GV parameters that describe level 2 hypoglycaemia (<54 mg/dl) were the strongest contributors to this association. 
Table legend: 
GV: glycaemic variability; HRV: heart rate variability; MBG: mean blood glucose; DD: diabetes duration (time since diagnosis, years); CGM: continuous glucose monitoring; SD: standard 
deviation; COV: coefficient of variation; CAN: cardiac/cardiovascular autonomic neuropathy; CART: cardiovascular autonomic reflex test.  
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